
Orchestra BioMed Holdings, Inc. (OBIO) Stock Ticker
OBIO right now
Market factors today
Unlock the full OBIO picture
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
OBIO stock facts
| Ticker symbol | OBIO |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $356.3M |
| CEO | David Hochman |
| Employees | 86 |
| Headquarters | New Hope, PA, US |
| IPO date | 2020-08-04 |
| Website | orchestrabiomed.com |
What you can see for OBIO on Tickr
Live OBIO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the OBIO report.
Rankings
FAQ
What is the ticker symbol for Orchestra BioMed Holdings, Inc.?
The ticker symbol for Orchestra BioMed Holdings, Inc. is OBIO, listed on the NASDAQ Global Market.
What is OBIO?
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for…